Both epidemiological and experimental findings suggest the possible roles of sex steroids in the pathogenesis and/or development of various human thyroid disorders. In this study, we evaluated the expression of estrogen receptors (ER) ␣ and ␤ in normal thyroid glands (N ‫؍‬ 25; female: n ‫؍‬ 13, male: n ‫؍‬ 10, unknown: n ‫؍‬ 2) ranging in age from fetus to adult. Furthermore, using immunohistochemistry, we investigated the expression of ER␣ and ␤ in 206 cases of thyroid disorders, including 24 adenomatous goiters, 23 follicular adenomas, and 159 thyroid carcinomas. In addition, we also studied the mRNA expression of ER␣ and ␤ and 17␤-hydroxysteroid dehydrogenase Type 1 and 2, enzymes involved in the interconversion between estrone and estradiol, using reverse transcription polymerase chain reaction (RT-PCR), in 48 of these 206 cases (10 adenomatous goiters, 10 follicular adenomas, and 28 papillary thyroid carcinomas) in which fresh frozen tissues were available for examination to further elucidate the possible involvement of intracrine estrogen metabolism and/or actions in thyroid disorders. ER␣ labeling index, or percentage of cells immunopositive for ER␣, was significantly higher in adenomatous goiter (14.2 ؎ 6.4), follicular adenoma (13.4 ؎ 5.1), and thyroid carcinoma (16.4 ؎ 2.1) than in normal thyroid gland (0; P < .05). Few follicular cells were positive for ER␣ in normal thyroid glands. In papillary carcinoma, ER␣ labeling index was significantly higher in premenopausal women (28.1 ؎ 4.5) than in postmenopausal women (14.2 ؎ 2.9) and in men of various ages (7.6 ؎ 2.7; P < .05). In other histological types of thyroid carcinoma, no significant correlations were detected. ER␤ immunoreactivity was detected in both follicular and C-cells of normal thyroid glands, including those in developing fetal thyroid glands. In addition, ER␤ immunoreactivity was detected in the nuclei of various thyroid lesions. But no significant correlations were detected between ER␤ labeling index and clinicopathological findings including age, menopausal status, gender, and/or histological type of thyroid lesions. 17␤-hydroxysteroid dehydrogenase Type 1 expression was detected in 31/48 (64.0%) of the cases examined, whereas Type 2 was detected only in 3/46 (6.3%) of all the cases examined. These results demonstrated that estrogens may influence the development, physiology, and pathology of human thyroid glands, and these effects, especially through ER␣, may become more pronounced in neoplasms, particularly in papillary carcinoma arising in premenopausal women. Biological effects of estrogens are generally mediated through an initial interaction with the estrogen receptor (ER), a member of the superfamily of nuclear receptors. Identification of ER is an initial step in understanding the estrogenic effects on various
tumors. ER has been identified, for instance, in a wide range of human neoplasms, including carcinoma arising in colon (1), lung (2) , pancreas (3) , and other organs classically considered not to be targets for estrogens. However, their biological significance in these tumors has not been fully elucidated. Thyroid tumors are well known to occur with approximately three times more frequency in women than in men (4) . Given the higher incidence and relatively better prognosis of thyroid carcinomas diagnosed in women (5) , especially in premenopausal women, it is reasonable to speculate that these thyroid lesions may be influenced by sex hormones, especially estrogens, in their pathogenesis and/or development.
In addition to the classical ER␣ isoform, a second isoform of ER or ER␤, has been recently identified in humans (6) . ER␤ has been demonstrated to be widely distributed in various human tissues (7, 8) , including many organs of the human fetus (9, 10) in contrast to ER␣. Several investigators have demonstrated the presence of ER␣ in thyroid tissues from human thyroid tumors and normal thyroid glands (11) (12) (13) , but not that of ER␤. In addition, Valle et al. (11) reported an overexpression of aromatase, the enzyme involved in conversion of androgens to estrogens, in several human thyroid lesions. However, results of these studies on ER␣ in normal and pathologic human thyroids have been inconsistent and could not necessarily account for the marked prevalence of thyroid lesions among female subjects. 17␤-Hydroxysteroid dehydrogenase catalyzes the reversible interconversion between estrone and estradiol. However, 17␤ reduction and oxidation of estrogens is catalyzed by different 17␤-hydroxysteroid dehydrogenase isozymes. 17␤-hydroxysteroid dehydrogenase Type 1 mainly catalyzes the conversion of inactive estrogen, estrone, to the biologically active estrogen, estradiol (14 -16) , whereas 17␤-hydroxysteroid dehydrogenase Type 2 predominantly catalyzes the conversion of estradiol to estrone (17) . 17␤-hydroxysteroid dehydrogenase Type 1 and 2 both are known to regulate the in situ levels of estradiol, and subsequently to modulate estrogenic actions in estrogen target tissues. Examination of 17␤-hydroxysteroid dehydrogenase Type 1 and 2 in human thyroid lesions, in addition to aromatase and ER isoforms, therefore, become very important in obtaining a better understanding of the local or intracrine regulation of estrogenic actions in human thyroid lesions. Therefore, in this study, we first examined the expression of ER␣ and ␤ in normal thyroid glands obtained from fetal, pediatric, and adult patients. We then studied the expression of ER␣ and ␤, and 17␤-hydroxysteroid dehydrogenase Types 1 and 2 in adenomatous goiters (n ϭ 24), follicular adenomas (n ϭ 23), and thyroid carcinomas (n ϭ 159), using immunohistochemistry and reverse transcription polymerase chain reaction (RT-PCR) to elucidate the possible roles of estrogens in the development, physiology, and pathology of the human thyroid gland.
MATERIALS AND METHODS

Tissue Preparation
Human fetal tissues (10 -21 weeks gestational age) were obtained after elective termination in normal pregnant women at Tohoku University Hospital and Nagaike Maternal Clinic (Sendai, Japan). Informed consent was obtained from these pregnant women before elective termination. The ages of the fetuses were estimated by the last menstrual date, body weight, and/or crown-rump length. Human fetal tissues of 24, 27, 37, and 39 weeks of age were obtained at the time of autopsy at Tohoku University Hospital. The ethics committee of Tohoku University School of Medicine approved this research protocol. The time elapsed from demise to the removal of the tissues ranged from 30 minutes to 1 hour in the case of elective termination, and from 2 to 6 hours in autopsy cases. After careful evaluation, these specimens did not appear to have any significant histopathological abnormalities. The specimens for immunohistochemistry were fixed in 10% neutral formalin for 18 hours at 4°C and then embedded in paraffin.
Patients and Tissues
Paraffin-embedded blocks from 206 patients who underwent thyroidectomy from 1990 to 2000 at Tohoku University Hospital, Sendai City Hospital, and Itou Hospital (Tokyo, Japan) were used for immunohistochemical studies. The mean age of the patients was 52.8 Ϯ 17.5 years old (range, 12-86 y). Twenty-four cases of adenomatous goiter (18 females, 6 males; 53.5 Ϯ 1.0 y), 23 cases of follicular adenoma (17 females, 6 males; 48.1 Ϯ 14.9 y), and 159 cases of carcinoma (116 females, 43 males; 53.8 Ϯ 17.5 y) were retrieved from the surgical pathology files at all three hospitals mentioned above. Carcinoma cases that we examined included 100 papillary (79 females, 21 males; 53.5 Ϯ 17.6 y), 14 follicular (8 females, 6 males; 47.6 Ϯ 17.5 y), 25 anaplastic (15 females, 10 males; 65.2 Ϯ 9.1 y), and 20 medullary (14 females, 6 males; 45.7 Ϯ 18.6 y) carcinomas (Table 1 ). All patients examined in this study received neither irradiation nor chemotherapy before surgery. The World Health Organization classification of thyroid lesions and the general rules for the description of thyroid cancer in Japan (18) were used as the basis for histological classification of thyroid tumors investigated in this study.
Fresh thyroid tissues were available for total RNA extraction and RT-PCR examination in 48 patients with thyroid disease from 1997 to 2000 at the three institutions above. Thyroid tissues were immediately frozen in liquid nitrogen and stored at Ϫ80°C until use for the RT-PCR study. The mean age of the patients was 53.3 Ϯ 15.5 years (range, 20 -86 y). These 48 cases included 28 papillary carcinomas (21 females, 7 males; 55.8 Ϯ 16.2 y), 10 follicular adenomas (8 females, 2 males; 47.2 Ϯ 14.6 y), and 10 adenomatous goiters (9 females, 1 males; 52.7 Ϯ 13.9 y). All of these cases were histologically confirmed.
Antibodies
The polyclonal antibody for ER␤ was raised in rabbit against synthesized peptides of the C-terminal region of ER␤ (CSPAEDSKSKEGSQN-PQSQ). This antibody was purified on affinity columns bound with the synthetic peptide. The characterization of this antibody was confirmed by Western blotting (19) , and use of the ER␤ antibody for immunohistochemistry has been previously reported. The monoclonal antibody for ER␣ (ER1D5) was purchased from Immunotech (Marseille, France).
Immunohistochemistry
In this study, immunohistochemical analyses were performed using the streptavidin-biotin amplification method and a Histofine Kit (Nichirei, Tokyo, Japan) for ER␣, and Envisionϩ (DAKO, Carpinteria, CA) for ER␤. For antigen retrieval, slides were deparaffinized and heated in an autoclave at 120°C for 5 minutes in a citric acid buffer (2 mM citric acid and 9 mM trisodium citrate dehydrate, pH 6.0) for the immunostaining of ER␣ and ER␤. The dilutions of primary antibodies used in this study were as follows: ER␣ 1/100, and ER␤ 1/100. The antigen-antibody complex was visualized with 3.3-diaminobenzidine (3,3'-diaminobenzidine) solution M 3,3'-diaminobenzidine, 50 mM Tris-HCl buffer [pH 7.6], and 0.006% H 2 O 2 , and counterstained with hematoxylin. Breast cancer was used as a positive control for ER␣, and normal breast was also used as a positive control for ER␤. Normal rabbit or mouse IgG was used instead of the primary antibodies as a negative control. No specific immunoreactivity was detected in these sections.
RT-PCR Analysis
Total RNA was extracted by homogenizing tissue specimens in guanidium thiocyanate, followed by ultracentrifugation in cesium chloride. Total RNA was spectrophotometrically quantified at 260 nm. An RT-PCR kit (SUPERSCRIPT Preamplification system, Gibco-BRL, Grand Island, NY) was employed in the synthesis and amplification of cDNA. cDNAs were synthesized from 5 g of total RNA using random hexamer primer. Reverse transcription was carried out for 60 minutes at 42°C with SUPERSCRIPT II reverse transcriptase. After an initial 1-minute denaturation step at 95°C, 40 cycles of PCR were carried out on a Light Cycler PCR machine (Roche Diagnostics GmbH, Mannheim, Germany) under the following condition: 0 seconds of denaturation at 95°C, 15 seconds of annealing at 62°C for ER␣ or at 60°C for ER␤ and GAPDH, followed by a 15-second extension at 72°C. The primer sequences used in this study are listed in Table 2 (21-24). After PCR, the products were resolved on a 2% agarose ethidium bromide gel, and images were captured with Polaroid film under ultraviolet transillumination. In initial experiments, amplified PCR products were purified and subjected to direct sequencing (ABI PRISM Biosystems, Foster City, CA; and ABI Prism 310 Genetic Analyzer) to verify amplification of the correct sequences. As a positive control, T-47D breast cancer cells were used for ER␣ and ER␤; frozen placental tissue was used as a positive control for 17␤-HSD Type 1 and 2. In the present study, we tested for the presence of exogenous and/or non-gene-specific contaminant DNA by synthesizing cDNA in the absence of reverse transcriptase and also by performing a standard PCR without cDNA substrate. We observed no amplification of gene-specific products under either of these conditions.
Scoring of Immunoreactivity
Scoring of ER␣ and ER␤ in tumor cells was performed on high-power field (400ϫ) using a standard light microscope. In each case, the fields for examination were simultaneously determined by two of the authors (WK and TS) using a doubleheaded light microscope. More than 1000 tumor cells were counted independently by the two authors above. Nuclear immunoreactivity was considered positive regardless of immunointensity. The Normal  3  3  5  11  Adenomatous goiter  7  11  6  24  Follicular adenoma  10  7  6  23  Carcinoma  47  69  43  159  Papillary  35  44  21  100  Follicular  5  3  6  14  Anaplastic  0  15  10  25  Medullary  7  7  6  20  Total  67  91  59  217 percentage of positive immunoreactivity, that is, labeling index, was determined. When interobserver differences were Ͼ5%, the cases were simultaneously re-evaluated using a double-headed light microscope. When interobserver differences were Ͻ5%, the mean values of these two observed data were determined as the labeling index for that case.
Interobserver differences in our study were Ͻ1%.
Statistical Analysis
The gender and menopausal status of the patients in this study were tentatively classified into three groups (premenopausal women, postmenopausal women, and men of various ages). Values for each category and the labeling index for ER␣ and ER␤ are presented as mean Ϯ standard error of means (SEM). Associations between the labeling index for ER␣ and ER␤ and each histological category were evaluated using an ANOVA test. A P-value of Ͻ.05 was considered significant.
RESULTS
Immunohistochemistry
Results are summarized in Tables 3 and 4. ER␣ ER␣ immunoreactivity was detected in the nuclei of invasive ductal carcinoma employed as positive control of immunostain. Very few follicular cells were positive for ER␣ in the normal thyroid gland of both women and men. ER␣ immunoreactivity was not detected in the nuclei of follicular cells in developing fetal thyroid glands. However, ER␣ immunoreactivity was detected in the nuclei of parenchymal cells in thyroid disorders (Fig. 1, A-D Results of the correlation between ER␣ labeling index and clinicopathological parameters are summarized in Table 3 . ER␣ labeling index was significantly higher in adenomatous goiter (14.2 Ϯ 6.4), follicular adenoma (13.4 Ϯ 5.1), and thyroid carcinoma (16.4 Ϯ 2.1%) than in normal thyroid gland (0; P Ͻ .05). In papillary carcinoma, ER␣ labeling index was significantly higher in premenopausal women (28.1 Ϯ 4.5) than in postmenopausal women (14.2 Ϯ 2.9) and men of various ages (7.6 Ϯ 2.7; P Ͻ .05). With respect to anaplastic carcinoma, ER␣ labeling index tends to be higher in men of various ages (34.7 Ϯ 10.1) than in postmenopausal women (8.2 Ϯ 5.4), but the differences did not reach statistical significance. No significant correlations were detected in other histological types. Clinical follow-up data of these patients with thyroid carcinoma also were not available for present study.
ER␤ ER␤ nuclear immunoreactivity was detected widely in both follicular or parenchymal and C-cells of normal thyroid glands, including those in the developing fetal thyroid glands (Fig. 1, E-F 17 .0 Ϯ 2.9 in papillary carcinoma, 15.5 Ϯ 5.3 in follicular carcinoma, 39.9 Ϯ 5.6 in anaplastic carcinoma, and 24.0 Ϯ 7.9 in medullary carcinoma.
Results of the correlation between ER␤ labeling index and clinicopathological parameters of patients were summarized in Table 4 . ER␤ labeling index tended to be higher in anaplastic carcinoma (39.9 Ϯ 5.6) than in other histological types, but the differences did not reach statistical significance. There were no significant correlations between ER␤ labeling index and patient age, menopausal status, gender, benign and malignant tumors, histological type and follow-up data (data not shown).
RT-PCR
Messenger RNA (mRNA) expression for ER␣, ER␤, and 17␤-hydroxysteroid dehydrogenase Type 1 and 2 was detected as a signal gene-specific band (168 bp for ER␣, 228 bp for ER␤, 352 bp for 17␤-hydroxysteroid dehydrogenase Type 1, and 418 bp for 17␤-hydroxysteroid dehydrogenase Type 2; Fig.  2 ) in 48/48 (100%), 48/48 (100%), 31/48 (64.6%), and 3/48 (6.3%) specimens examined, respectively. Results of RT-PCR analysis were consistent with those of immunohistochemistry in each case.
No significant correlations were detected between 17␤-hydroxysteroid dehydrogenase Type 1 and the labeling index for ER␣ and ␤, or between 17␤-hydroxysteroid dehydrogenase Type 2 and the labeling index for ER␣ and ␤.
DISCUSSION
In our present study, ER␣ immunoreactivity was not detected in the normal thyroid gland, but ER␤ immunoreactivity was detected in the nuclei of follicular epithelial cells and C-cells throughout the development of the normal thyroid gland. The presence of ER␤ previously has been demonstrated in the normal rat thyroid gland by immunohistochemistry (24) . In addition, ER␤ has very recently been demonstrated in adult normal human thyroid gland by immunohistochemistry (8) . Results from our present study are also consistent with those from previous studies. In our study, ER␤ immunoreactivity was detected throughout the development of the human thyroid gland from 11 gestational weeks. In normal pregnancy, large quantities of estrogens are produced by placental syncytiotrophoblasts, which subsequently move into both the fetal and maternal circulation. The effects of estrogens on thyroid development have not been well studied, but results of our present study suggest that estrogens may also be involved in the development of fetal thyroid glands. These effects are most likely to be predominantly mediated via ER␤.
ER␣ immunoreactivity was detected in the nuclei of thyroid parenchymal cells of various thyroid lesions. The presence of ER␣ has previously been examined in human thyroid neoplasms by a number of investigators (11) (12) (13) (25) (26) (27) . However, results from these studies were inconsistent, possibly because of the different methods employed. In our present study, we employed immunohistochemistry in combination with labeling index, one of the most reliable methods for detecting ER␣ in clinical specimens, and also RT-PCR. ER␣ labeling index was significantly higher in adenomatous goiters, follicular adenomas and thyroid carcinomas than in normal thyroid glands. In the papillary carcinoma, ER␣ labeling index was significantly higher in postpuberty/premenopausal women than in postmenopausal women and men of various ages. A statistically significant association between ER␣ and the age of the patients was not detected in other types of thyroid lesions. Estradiol has been demonstrated to stimulate cell proliferation of FRTL-5 rat cells, a well-established cell line derived from thyroid papillary carcinoma (28) , and the human thyroid papillary carcinoma cell line, HTCTSHr (29) . These results all suggest that higher estrogen concentrations in the serum may be responsible for the relatively high incidence of thyroid papillary carcinoma in premenopausal women. In addition, a higher level of ER␣ labeling index may also be involved in the activation of tumorigenesis of papillary carcinoma in premenopausal women, but it awaits further investigations for clarification. The status of ER␤ has not been well studied in human thyroid disorders. In our present study, ER␤ nuclear immunoreactivity was detected relatively widely in thyroid neoplastic parenchymal cells. There were, however, no significant correlations between ER␤ immunoreactivity and any clinicopathological parameters examined, including patient age, menopausal status, gender, histological type, and fetal developmental stage. In addition, ER␤ is widely distributed in follicular cells and C-cells of the normal thyroid gland throughout development. These results above suggest that estrogenic effects via ER␤ play important roles in the maintenance of homeostasis of thyroid follicles, and possibly of thyroid hormone biosynthesis.
P450 aromatase converts androstenedione to estrone and testosterone to estradiol. Recent studies demonstrated that bioactive estrogen, estradiol, is produced locally in breast carcinoma (30) . Estrogen also has been reported to be produced locally in human thyroid tumors (11) . In addition, aromatase immunoreactivity has been demonstrated to be expressed in the cytoplasm of follicular epithelial cells (11) . In our present study, the expression of 17␤-hydroxysteroid dehydrogenase Types 1 and 2 was demonstrated by RT-PCR. Especially, 17␤-hydroxysteroid dehydrogenase Type 1 was detected in 31/48 (64.0%) of the cases examined. Expression of ER, aromatase, and 17␤-hydroxysteroid dehydrogenase Type 1 has been demonstrated in human thyroid lesions as in human breast carcinoma (30) .
This mechanism can effectively produce estrogens in situ from circulating androgens and exert their effects locally. Further investigations are required to fully elucidate the roles and mechanisms of estrogenic actions with respect to pathogenesis and/or development of human thyroid disorder.
